Navigation Links
Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
Date:9/27/2007

SOUTH SAN FRANCISCO, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that the Company's common shares are now eligible to be included in the NASDAQ Global Market and will begin trading there under the same symbol "PARD" effective Monday, October 1, 2007.

"Qualifying for listing on the NASDAQ Global Market represents an important milestone for Poniard and provides us with greater visibility in the global financial markets and broadens our exposure to new investors," said Caroline Loewy, chief financial officer of Poniard. "This is an important step in our continued growth and demonstrates our ability to meet the higher standards required by the NASDAQ Global Market."

NASDAQ-listed companies are classified under three listing tiers -- NASDAQ Global Select Market, NASDAQ Global Market and NASDAQ Capital Market. Poniard has been listed on the NASDAQ Capital Market. All three market tiers maintain rigorous listing and corporate governance standards. For additional information about the NASDAQ Global Market, please visit http://www.nasdaq.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead product candidate, is a new generation platinum therapy with an improved safety profile. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors. Intravenous picoplatin is currently being studied in clinical trials for the treatment of small cell lung, colorectal and hormone-refractory prostate cancer, and oral picoplatin is in a clinical trial in solid tumors. As part of the Company's strategic goal of building a diverse oncology pipeline, the Company is collaborating with The Scripps Research Institute on the discovery of novel, small-molecule, multi-targeted protein kinase inhibitors. For additional information please visit http://www.poniard.com.

(C) 2007 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ON (PRWEB) , ... May 05, 2016 , ... ... following the previously announced identification of its first three targets, it has identified ... misfolded Amyloid beta (Aß), implicated in the development and progression of Alzheimer’s disease ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering ... need to give mom an experience she won’t forget. , Guests that visit ...
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research "Metabolomics Market - Global Industry ... 2024", the metabolomics market is anticipated to expand at ... reach USD 2,494.8 million by 2024. Metabolomics ... as metabolites, within cells, biofluids, tissues or organisms. Together, ...
Breaking Biology Technology:
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
Breaking Biology News(10 mins):